Angiotensin II Type 2‐Receptor: New Clinically Validated Target in the Treatment of Neuropathic Pain

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|97|2|128-130

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.97, Iss.2, 2015-02, pp. : 128-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension

By  

Nephron Clin Pract, Vol. 108, Iss. 4, 2008-04 ,pp. : c291-c297

Karger

Access to resources Recommend Favorite

Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice

By Maul Björn  

Journal of Molecular Medicine, Vol. 86, Iss. 5, 2008-05 ,pp. : 563-571

Springer Publishing Company

Access to resources Recommend Favorite

Vasodilation Mediated by Angiotensin II Type 2 Receptor Is Impaired in Afferent Arterioles of Young Spontaneously Hypertensive Rats

By  

Journal of Vascular Research, Vol. 35, Iss. 6, 2008-09 ,pp. : 421-427

Karger

Access to resources Recommend Favorite

Best practices in the treatment of neuropathic pain

By Elmofty Dalia H   Anitescu Magdalena   Buvanendran Asokumar  

Pain Management, Vol. 3, Iss. 6, 2013-11 ,pp. : 475-483

Future Medicine

Access to resources Recommend Favorite

Individualized Pharmacological Treatment of Neuropathic Pain

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 135-142

John Wiley & Sons Inc

Access to resources Recommend Favorite